Better Buy: Celgene vs. Gilead Sciences
Which stock wins in a battle between these two big biotechs?
https://fool.com/investing/2019/09/14/better-buy-celgene-vs-gilead-sciences.aspx $CELG $GILD
Sorry, don’t know
Do you or anyone here know the tax treatment of the CVR??
Advances in Cancer Drugs Fuel Deal -- WSJ
Yep, I like BMY and the deal. Very fair to put a $9 a share bonus for the 3 NDA's they have been working on.
Good call, a good analyst always starts with a low upside and then can move up. Are you moving up. RCPT killed CELG, I was lucky CELG bought it I guess as it was a 300% winner for us.
This could be a very good fit with BMY
I thought I was a genius when I bought these guys at 88. I'm stunned at how poorly they have been managed. Interested in your insights going forward. Thanks for the comments.
I don’t know. But, there was some dialog on Twitter over the last several days about some issue with one of their trials. They have made some bonehead moves over the last few years.
Now is the time to buy for a trade 63 to 71...thoughts?
Celgene Corp $CELG Chart Signals Trouble
Shares of Celgene Corp (CELG) have a nasty chart and pro traders are alerting investors. The stock price is currently forming a classic bear flag pattern. To make matters worse, the daily 20, 50 and 200 moving averages are just above current price and turning lower. This signals a likely fall on Celgene Corp in the coming weeks to as low as $75.00.
Breakout Alert: Celgene $CELG
Shares of Celgene Corp (CELG) are beginning to breakout on the daily stock chart. This pattern setup is fantastic as money is beginning to flow from over-bought sectors to under-bought sectors. In a market priced to perfection, the biotechnology stocks have drastically lagged. Their valuations are extremely attractive compared to an Amazon (AMZN) and Netflix (NFLX). The Celgene stock chart has formed a beautiful bull flag just off the 52 week lows. Today, the breakout is beginning as the stock is up over 2% and cracking the upper band trend line. Look for an upside target of $86 in the near-term.
Now I know why they call it the Motley Fool...
Surprised that the CEO of Celgene, Mark Alles, is still heading the firm. Commentary from other individuals indicate he is in over his head, and I tend to agree.. should be removed. The board should be a target as the have abandoned their fiduciary responsibility by adding all the additional titles to Alles.
CELG remains volatile because of several product issues as well as approaches to biotech. CELG leading indicators highlighted the downward trend in November 2017, and has remained in a negative zone, despite the temporary rebounds.
$CELG - Prothena Announces Global Neuroscience Research & Development Collaboration with Celgene for Novel Therapies for Patients with Neurodegenerative Diseases
Celgene Corp $CELG Is Trending Down, Know This Level
Leading biotechnology stock Celgene Corp (NASDAQ:CELG) has been trending lower since October 2017. At that time, the stock traded as high as $147.17 a share. Today, CELG stock is trading around the $87.00 area. Traders can easily see how this stock has fallen from grace over the past five months. The stock is now trading below its 50 and 200 week moving averages, this is a very negative chart formation. The stock should now find some solid support around the $82.75 area. This is a major retrace level where the stock could bounce from the current oversold condition.
$CELG 7 Companies We'd Buy and Hold for the Next 20 Years
Three huge screw ups recently. That huge swishing sound you hear are the institutional holders dumping their shares. Time to enter..
Rallying back hard...
Sold at limit sell 1.25
It seems to me that the selloff is considerably overblown.
CELG still has an impressive pipeline, cash and a talent for picking up new drugs very profitably.
As this drop illustrates, there is a substantial failure rate in clinical trials, but the market gasps and clutches it's proverbial breast in surprise each time.
Seems to me to be a very clear BUY signal, and i will as soon as it stops sinking!
Celgene longs--be smart--move your biotech $$$$$$ to Anavex (Avxl)---fantastic future with CNS drugs---Alzheimer's--Parkinsons---Rett Syndrome---depression etc----huge winner here !!!!!! 3 clinical trials stating this year---huge possibility for success !!!!
Noticed AH drop in share price, thank you. We hold no CELG except as it may be in portfolios of LABU or FBIOX...likely in both.
Celgene Provides Update on GED-0301 (mongersen) Inflammatory Bowel Disease Program
CELG: looks like no link available from IBD Weekly 'til Monday.
IBD names CELG as #1 in a new feature---its Innovator Awards 2017---for "groundbreaking treatments recently introduced to the market or well along in the new-product pipeline."
BIIB, REGN, INCY, KITE and LOXO are also named. I will post a link later---the text occupies several pages.
Both Folkman's name and D'Amato's appear across a surprisingly diverse range of fields. Literally awesome people!
Our culture is so stupidly stuck in a positive-negative, win-fail mind set that we learn less and less from our mistakes..
A self handicapping mindset.
Most every novel screw up. is a potential technique in another context....If we can learn from them.
I agree 100%
A big thank needs to go out to The late great Dr. Moses Judah Folkman and Dr. Robert D'Amato for their hypothesis that thalidomide has anti-angiogenesis properties that allow it to cut off the blood supply to cancerous tumors.
Good luck and GOD bless,
It's true..Out of that disastrous drug error, CELG has changed the problematic chemistry and saved or benefitted millions of sick folks.
They've also done very nicely for my stock portfolio.
Every mistake is a learning opportunity.
Some of our most important medicines were discovered thus.
This Leading Biotechnology Level Should Be On The Radar
One of the leading biotechnology stocks in the world is Celgene Corporation (NASDAQ:CELG). This company discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases. Celgene stock topped out on March 17th at $127.64 a share. Today, Celgene stock is trading at $116.97 a share. Traders can easily see that this leading biotechnology stock has been trending lower on the charts lately. The stock now has major chart support around the $110.00 level. This is an area where the major institutional money supported the equity back in December 2016. Often, old pivot levels will serve as major chart support when retested.
Celgene: Otezla (Apremilast), Revlimid (Lenalidomide), Pomalyst in the U.S. and Imnovid in EU and Russia (Pomalidomide) are all derived from the notorious sedative thalidomide. Celgene has built a multibillion dollar business based on thalidomide and its derivatives.
86 Morris Avenue
Summit, NJ 07901
Phone: (908) 673-9000
Celgene Corporation, a publicly traded company…
Committed to Improving the Lives of Patients Worldwide
Celgene is a multinational biopharmaceutical company committed to improving the lives of patients worldwide.
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
There are numerous clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), glioblastoma, and ovarian, pancreatic and prostate cancer.
As committed as we are to clinical accomplishment, we are equally committed to
Our portfolio of services and pharmaceutical products in the U.S. include:
|® (melphalan) tablets|
|® (melphalan) for injection|
|® (azacitidine for injection)|
|(placental and cord blood banking)|
American Stock Transfer & Trust Company
59 Maiden Lane
New York 10038
Last update 4.12.2010
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Rules of the board according to IHUB: